ALLIGATOR BIOSCIENCE NPVALLIGATOR BIOSCIENCE NPVALLIGATOR BIOSCIENCE NPV

ALLIGATOR BIOSCIENCE NPV

No trades
See on Supercharts

0RK9 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Alligator Bioscience AB is a biotechnology company, which engages in the development of novel immuno-oncology drugs. The firm specializes in the development of tumor-directed immunotherapies. Its pipeline includes Mitazalimab, ATOR-1017, ALG.APV-527, Neo-X-Prime, and other research projects. The company was founded by Carl Arne Krister Borrebaeck in 2001 and is headquartered in Lund, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
0RK9 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company